Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252308 | 0.86 | ALDH1A1 (0.58) | ALDH1A1LMNAADRB2KDM4ESMN1; SMN2 | |
| SCHEMBL7037234 | 0.86 | RXFP1 (0.46) | ALDH1A1LMNAKDM4EL3MBTL1MEN1 | |
| SCHEMBL7039230 | 0.86 | CHRNB2 (0.51) | ALDH1A1LMNAKDM4EHTTL3MBTL1 | |
| SCHEMBL7039859 | 0.85 | CHRNB2 (0.47) | ALDH1A1LMNAKDM4EL3MBTL1MEN1 | |
| SCHEMBL7041358 | 0.83 | ALDH1A1 (0.51) | ALDH1A1LMNAHTTL3MBTL1MEN1 | |
| SCHEMBL7041084 | 0.81 | LMNA (0.46) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL7041929 | 0.81 | L3MBTL1 (0.50) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL7038646 | 0.79 | KMT2A (0.54) | ALDH1A1LMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL7035898 | 0.79 | MTTP (0.50) | KDM4EGAA | |
| SCHEMBL7036532 | 0.79 | POLB (0.54) | ALDH1A1LMNAKDM4EHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | ALDH1A1 2713/4885LMNA 1024/4885ADRB2 1441/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | ALDH1A1 756/4885LMNA 2520/4885ADRB2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.